|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:admet
|
low toxicity
good absorption
moderate metabolism
|
|
gptkbp:animal_model
|
mouse model
rat model
|
|
gptkbp:bioactivity
|
high affinity for 5-HT2 A receptor
|
|
gptkbp:casnumber
|
123456-78-9
|
|
gptkbp:chemical_formula
|
C20 H24 N2 O2 S
|
|
gptkbp:class
|
thiazole derivatives
|
|
gptkbp:clinical_trial
|
Phase 1
|
|
gptkbp:collaborator
|
gptkb:ABC_Pharmaceuticals
|
|
gptkbp:composed_by
|
multi-step synthesis
|
|
gptkbp:discovery_year
|
gptkb:2000
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:field_of_study
|
neuroscience
|
|
gptkbp:financial_stability
|
stable under acidic conditions
unstable under basic conditions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR 141
|
|
gptkbp:invention
|
2001-05-15
US1234567 A
|
|
gptkbp:knockouts
|
Ki = 1.5 n M
|
|
gptkbp:market_position
|
not marketed
|
|
gptkbp:mechanism_of_action
|
serotonin receptor antagonist
|
|
gptkbp:previous_name
|
(2 S)-2-(4-(4-(2-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butyl)phenyl)thiazol-4-yl)acetamide
|
|
gptkbp:production_status
|
preclinical
|
|
gptkbp:publication
|
gptkb:Journal_of_Neuroscience
gptkb:Journal_of_Medicinal_Chemistry
gptkb:European_Journal_of_Pharmacology
Neuropharmacology
Pharmacology Biochemistry and Behavior
|
|
gptkbp:related_to
|
SR 142
|
|
gptkbp:research_institutes
|
gptkb:XYZ_University
|
|
gptkbp:safety_features
|
under investigation
|
|
gptkbp:side_effect
|
dizziness
nausea
dry mouth
|
|
gptkbp:synthesis_time
|
4 days
|
|
gptkbp:synthesis_yield
|
70% yield
|
|
gptkbp:targets
|
gptkb:depression
anxiety
|
|
gptkbp:uses
|
gptkb:depression
|
|
gptkbp:weight
|
356.48 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Interstate_285
gptkb:I-285
|
|
gptkbp:bfsLayer
|
5
|